{"id":447,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","title":{"rendered":"Se\u00f1alizaci\u00f3n Tirzepatide dual GIP\/GLP-1: explicaci\u00f3n del mecanismo y los criterios de valoraci\u00f3n de la prueba"},"content":{"rendered":"
Tirzepatide es un p\u00e9ptido acilado dise\u00f1ado para activar tanto el receptor del polip\u00e9ptido insulinotr\u00f3pico dependiente de glucosa (GIP) como el receptor del p\u00e9ptido similar al glucag\u00f3n-1 (GLP-1). Comprender que la farmacolog\u00eda dual requiere separar la actividad del receptor de los resultados cl\u00ednicos medidos en poblaciones espec\u00edficas.<\/p>
Conclusiones clave<\/h2>
Tirzepatide es un agonista dual del receptor GIP\/GLP-1, no un \u201cagonista triple\u201d.<\/li>
Los ensayos SURPASS se centraron en los resultados de la diabetes tipo 2; Los ensayos SURMOUNT se centraron en los resultados relacionados con la obesidad.<\/li>
Los datos de medicamentos terminados aprobados por FDA no establecen la calidad, seguridad o eficacia de un material del cat\u00e1logo de uso en investigaci\u00f3n no relacionado.<\/li><\/ul><\/div><\/div>Ilustraci\u00f3n editorial original de la investigaci\u00f3n de p\u00e9ptidos multirreceptores. Es una escena de laboratorio conceptual, no una imagen de producto o tratamiento.<\/figcaption><\/figure>
\u00bfQu\u00e9 significa el agonismo del receptor dual?<\/h2>
GIP y GLP-1 son sistemas de se\u00f1alizaci\u00f3n que responden a nutrientes con acciones distintas y superpuestas. Tirzepatide fue dise\u00f1ado como una mol\u00e9cula capaz de activar ambos receptores. El efecto cl\u00ednico es el resultado de la farmacolog\u00eda, exposici\u00f3n y formulaci\u00f3n de toda la mol\u00e9cula; no se puede inferir simplemente sumando dos descripciones de v\u00edas separadas.<\/p>
La etiqueta FDA identifica tirzepatida como el ingrediente activo de productos recetados aprobados y describe indicaciones, advertencias y detalles de formulaci\u00f3n espec\u00edficos del producto. Esas declaraciones pertenecen al medicamento terminado aprobado que se menciona en la etiqueta.<\/p>
C\u00f3mo leer los programas de prueba<\/h2>
SURPASS-1 fue un ensayo de fase aleatorizado 3 en adultos con diabetes tipo 2 no controlada inadecuadamente con dieta y ejercicio. Su criterio de valoraci\u00f3n principal fue el cambio en la hemoglobina glucosilada, con el peso corporal y la seguridad entre los resultados adicionales. SURMOUNT-1 inscribi\u00f3 a adultos con obesidad o sobrepeso m\u00e1s una afecci\u00f3n relacionada con el peso y utiliz\u00f3 el cambio porcentual en el peso corporal como criterio de valoraci\u00f3n principal.<\/p>
La poblaci\u00f3n, el comparador, la duraci\u00f3n del tratamiento, la estimaci\u00f3n y el manejo de la interrupci\u00f3n afectan la interpretaci\u00f3n. Un porcentaje de t\u00edtulo nunca debe separarse de esos elementos de dise\u00f1o.<\/p>
SURPASS-1<\/strong>Fase 3, diabetes tipo 2, criterio de valoraci\u00f3n principal de control gluc\u00e9mico<\/span><\/div>
SURMOUNT-1<\/strong>Fase 3, poblaci\u00f3n con obesidad\/sobrepeso, criterio de valoraci\u00f3n principal de peso corporal<\/span><\/div>
Registro regulatorio<\/strong>Informaci\u00f3n de prescripci\u00f3n y lenguaje de seguridad espec\u00edficos del producto FDA<\/span><\/div><\/div><\/div>
Por qu\u00e9 es importante la equivalencia material<\/h2>
Los resultados del ensayo cl\u00ednico se aplican a la intervenci\u00f3n estudiada, fabricada y controlada bajo las condiciones de ese ensayo. La identidad de secuencia por s\u00ed sola no demuestra equivalencia en pureza, agregaci\u00f3n, contrai\u00f3n, esterilidad, carga de part\u00edculas, formulaci\u00f3n o estabilidad.<\/p>
Para el material de investigaci\u00f3n del cat\u00e1logo, los investigadores deben confiar en las especificaciones espec\u00edficas del producto y en la documentaci\u00f3n del lote. Las afirmaciones cl\u00ednicas de un medicamento aprobado no deben transferirse a la p\u00e1gina de un producto de uso en investigaci\u00f3n.<\/p>","protected":false},"excerpt":{"rendered":"
Una explicaci\u00f3n basada en evidencia del agonismo del receptor dual de tirzepatida y los criterios de valoraci\u00f3n medidos en los ensayos SURPASS y SURMOUNT, con l\u00edmites claros en la aplicaci\u00f3n de datos de f\u00e1rmacos a los materiales del cat\u00e1logo.<\/p>","protected":false},"author":1,"featured_media":617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"370","pim_article_type":"Clinical evidence explainer","pim_evidence_level":"Randomized phase 3 trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"SURPASS-1 randomized phase 3 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34186022\/\",\"note\":\"Primary clinical trial record; PMID 34186022.\"},{\"title\":\"SURMOUNT-1 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\",\"note\":\"Primary clinical trial record; PMID 35658024.\"},{\"title\":\"FDA prescribing information for Mounjaro (tirzepatide)\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf\",\"note\":\"Approved-finished-product regulatory record.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\" \/>\n<meta property=\"og:description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Se\u00f1alizaci\u00f3n Tirzepatide Dual GIP\/GLP-1: explicaci\u00f3n del mecanismo y los puntos finales de prueba - NHD","description":"Una explicaci\u00f3n basada en evidencia del agonismo del receptor dual de tirzepatida y los criterios de valoraci\u00f3n medidos en los ensayos SURPASS y SURMOUNT, con l\u00edmites claros en la aplicaci\u00f3n de datos de f\u00e1rmacos a los materiales del cat\u00e1logo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_locale":"es_ES","og_type":"article","og_title":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","og_description":"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.","og_url":"https:\/\/nhdbio.com\/es\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","url":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","name":"Se\u00f1alizaci\u00f3n Tirzepatide Dual GIP\/GLP-1: explicaci\u00f3n del mecanismo y los puntos finales de prueba - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Una explicaci\u00f3n basada en evidencia del agonismo del receptor dual de tirzepatida y los criterios de valoraci\u00f3n medidos en los ensayos SURPASS y SURMOUNT, con l\u00edmites claros en la aplicaci\u00f3n de datos de f\u00e1rmacos a los materiales del cat\u00e1logo.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=447"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/447\/revisions"}],"predecessor-version":[{"id":524,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/447\/revisions\/524"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Investigador](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")